COLOGUARD RESCREENING

The Cologuard® test maintained high adherence rates over time for repeated CRC screenings1

When screening with the Cologuard test, the US Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) both recommend a screening interval of every 3 years following a negative result.2,3*

80%

of Cologuard patients were adherent after having been prescribed a second screening1†

90%

of Cologuard patients were adherent after having been prescribed a third screening1‡

By comparison, the recommended screening frequency for FIT is every year – necessitating annual screening conversations and yearly patient adherence.2,3


Sign up for Cologuard updates.


Cologuard box.

Better outcomes with the Cologuard test

Discover how the Cologuard test compares to FIT in life-years gained.

Screen your eligible patients for CRC every 3 years with the Cologuard test to help increase adherence1-3

Send the Cologuard Rescreening Letter to your patients when they become eligible for rescreening with the Cologuard test

Patients are eligible for rescreening with the Cologuard test if they2-4:

Are aged 45 years or older

Are at average risk for CRC

Received a negative test result with previous Cologuard screening


PROVIDER STATUS REPORT

Get screening updates for your eligible patients

Sign up for biweekly fax updates summarizing which of your patients are due for rescreening with the Provider Status Report Enrollment Form. Forms are available for both single and multiple office locations.



  • *The USPSTF-recommended screening frequency for sDNA-FIT is every 1 to 3 years.2 The ACS-recommended screening interval for mt-sDNA is every 3 years.3 Guidelines may refer to the Cologuard test by different names, including mt-sDNA, FIT-fecal DNA, sDNA, and sDNA-FIT.
  • Based on patients who completed screening within 90 days of receiving Cologuard kits for their second CRC screening from October 2020 to December 2021.1
  • Based on adherence rates within 120 days of patients receiving Cologuard kits for their second and third CRC screening, respectively, from September of 2022 to July 2023.1